Abstract
We develop a framework for modelling the risk of infection from airborne Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in well-mixed environments in the presence of interventions designed to reduce infection risk. Our framework allows development of models that are highly tailored to the specifics of complex indoor environments, including layout, people movements, and ventilation. We explore its utility through case studies, two of which are based on actual sites.
Our results reflect previously quantified benefits of masks and vaccinations. We also produce quantitative estimates of the effects of air filters, and reduced indoor occupancy for which we cannot find quantitative estimates but for which positive benefits have been postulated.
We find that increased airflow reduces risk due to dilution, even if that airflow is via recirculation in a large space. Our case studies have identified interventions which seem to generalise, and others which seem to be dependent on site-specific factors, such as occupant density.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Previous confidential technical reports were funded by the Department of Industry, Science, Energy and Resources, Australia.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This project was approved by the CSIRO Health and Medical Human Research Ethics Committee (EC00187), project number 2021_103_LR.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Author-supplied statements Relevant information will appear here if provided.
Ethics
Does your article include research that required ethical approval or permits?: Yes
Statement (if applicable): This project was approved by the CSIRO Health and Medical Human Research Ethics Committee (EC00187), project number 2021_103_LR.
Data
It is a condition of publication that data, code and materials supporting your paper are made publicly available. Does your paper present new data?: Yes
Statement (if applicable): A snapshot of the Python package, scripts and results used in this work is available at https://doi.org/10.5281/zenodo.6911600, and the Python package and scripts are also available from Github https://github.com/Sleepingwell/apsrm.
Conflict of interest I/We declare we have no competing interests
Statement (if applicable): CUST_STATE_CONFLICT :No data available.
Journal to which it has been submitted.